Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ADMA Biologics faces a class action securities fraud lawsuit alleging the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth. A March 2026 report by Culper Research claimed ADMA induced distributors to stock excess inventory through rebates and extended payment terms, reporting false growth figures. The allegations led to a 29.1% stock price decline. Investors have until August 10, 2026 to file a lead plaintiff motion.